Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models

M. Tejeda, D. Gaál, L. Hullán, B. Hegymegi-Barakonyi, G. Kéri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The antitumor effects of the somatostatin structural derivative TT-232 in different rodent and xenograft tumor models are summarized in this report. TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of different tumors in animal models in vivo. The effects of TT-232 by different routes of administration and treatment schedules were studied in various types of rodent and human xenograft tumor models. In the rodent tumor models S-180 sarcoma and P-388 lymphoid leukemia tumor the infusion treatment resulted in 76%-100% tumor growth inhibition and in 20%-60% of the mice being long-term and tumor-free survivors. In the aggressive C-26 colon carcinoma and MXT breast carcinoma, the TT-232 treatments resulted in 71%-75% tumor growth inhibition and an approximately 50% increased survival time. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-40% tumor-free animals. This antitumor efficacy of TT-232 was seen in almost all the tumors investigated. In our study, the route of infusion was shown to increase drug efficacy relative to conventional delivery methods. Our results suggested that TT-232 is an effective and promising antitumor agent.

Original languageEnglish
Pages (from-to)3477-3483
Number of pages7
JournalAnticancer Research
Volume26
Issue number5 A
Publication statusPublished - Sep 2006

Fingerprint

Somatostatin
Neoplasms
Heterografts
Rodentia
TT2-32
Growth
Sarcoma 180
Lymphoid Leukemia
Tumor Burden
Antineoplastic Agents
Appointments and Schedules
Colon
Animal Models
Breast Neoplasms
Carcinoma

Keywords

  • Rodent and human tumor models
  • Somatostatin analog
  • TT-232

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. / Tejeda, M.; Gaál, D.; Hullán, L.; Hegymegi-Barakonyi, B.; Kéri, G.

In: Anticancer Research, Vol. 26, No. 5 A, 09.2006, p. 3477-3483.

Research output: Contribution to journalArticle

@article{0c466979a9c048de987aae881e9183f5,
title = "Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models",
abstract = "The antitumor effects of the somatostatin structural derivative TT-232 in different rodent and xenograft tumor models are summarized in this report. TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of different tumors in animal models in vivo. The effects of TT-232 by different routes of administration and treatment schedules were studied in various types of rodent and human xenograft tumor models. In the rodent tumor models S-180 sarcoma and P-388 lymphoid leukemia tumor the infusion treatment resulted in 76{\%}-100{\%} tumor growth inhibition and in 20{\%}-60{\%} of the mice being long-term and tumor-free survivors. In the aggressive C-26 colon carcinoma and MXT breast carcinoma, the TT-232 treatments resulted in 71{\%}-75{\%} tumor growth inhibition and an approximately 50{\%} increased survival time. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30{\%}-80{\%} decrease in tumor volume and in 20{\%}-40{\%} tumor-free animals. This antitumor efficacy of TT-232 was seen in almost all the tumors investigated. In our study, the route of infusion was shown to increase drug efficacy relative to conventional delivery methods. Our results suggested that TT-232 is an effective and promising antitumor agent.",
keywords = "Rodent and human tumor models, Somatostatin analog, TT-232",
author = "M. Tejeda and D. Ga{\'a}l and L. Hull{\'a}n and B. Hegymegi-Barakonyi and G. K{\'e}ri",
year = "2006",
month = "9",
language = "English",
volume = "26",
pages = "3477--3483",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models

AU - Tejeda, M.

AU - Gaál, D.

AU - Hullán, L.

AU - Hegymegi-Barakonyi, B.

AU - Kéri, G.

PY - 2006/9

Y1 - 2006/9

N2 - The antitumor effects of the somatostatin structural derivative TT-232 in different rodent and xenograft tumor models are summarized in this report. TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of different tumors in animal models in vivo. The effects of TT-232 by different routes of administration and treatment schedules were studied in various types of rodent and human xenograft tumor models. In the rodent tumor models S-180 sarcoma and P-388 lymphoid leukemia tumor the infusion treatment resulted in 76%-100% tumor growth inhibition and in 20%-60% of the mice being long-term and tumor-free survivors. In the aggressive C-26 colon carcinoma and MXT breast carcinoma, the TT-232 treatments resulted in 71%-75% tumor growth inhibition and an approximately 50% increased survival time. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-40% tumor-free animals. This antitumor efficacy of TT-232 was seen in almost all the tumors investigated. In our study, the route of infusion was shown to increase drug efficacy relative to conventional delivery methods. Our results suggested that TT-232 is an effective and promising antitumor agent.

AB - The antitumor effects of the somatostatin structural derivative TT-232 in different rodent and xenograft tumor models are summarized in this report. TT-232 had previously been shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of different tumors in animal models in vivo. The effects of TT-232 by different routes of administration and treatment schedules were studied in various types of rodent and human xenograft tumor models. In the rodent tumor models S-180 sarcoma and P-388 lymphoid leukemia tumor the infusion treatment resulted in 76%-100% tumor growth inhibition and in 20%-60% of the mice being long-term and tumor-free survivors. In the aggressive C-26 colon carcinoma and MXT breast carcinoma, the TT-232 treatments resulted in 71%-75% tumor growth inhibition and an approximately 50% increased survival time. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20%-40% tumor-free animals. This antitumor efficacy of TT-232 was seen in almost all the tumors investigated. In our study, the route of infusion was shown to increase drug efficacy relative to conventional delivery methods. Our results suggested that TT-232 is an effective and promising antitumor agent.

KW - Rodent and human tumor models

KW - Somatostatin analog

KW - TT-232

UR - http://www.scopus.com/inward/record.url?scp=33750739535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750739535&partnerID=8YFLogxK

M3 - Article

C2 - 17094470

AN - SCOPUS:33750739535

VL - 26

SP - 3477

EP - 3483

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -